Welcome to our dedicated page for Surmodics news (Ticker: $SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Surmodics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Surmodics's position in the market.
Surmodics, Inc. (Nasdaq: SRDX) reported Q2 FY 2024 results with total revenue of $32.0 million, a 18% increase YoY, excluding SurVeil™ DCB license fee revenue. GAAP net income was $0.2 million. The company launched two new thrombectomy devices, the Pounce™ Venous and Pounce LP, for venous and arterial vasculatures. Surmodics increased revenue and EPS guidance for FY 2024 due to strong performance and product launches, expecting $122-124 million in total revenue.